APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immunotherapeutic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Immunotherapeutic Drugs Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchImmunotherapeutic Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Immunotherapeutic Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Immunotherapeutic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immunotherapeutic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Immunotherapeutic Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Immunotherapeutic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Immunotherapeutic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Immunotherapeutic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Immunotherapeutic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Immunotherapeutic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Immunotherapeutic Drugs include Johnson & Johnson, Novartis, Merck, Roche, ELI Lilly, GlaxoSmithKline, Amgen, AbbVie and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Immunotherapeutic Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immunotherapeutic Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Immunotherapeutic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immunotherapeutic Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immunotherapeutic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Immunotherapeutic Drugs revenue, projected growth trends, production technology, application and end-user industry.

Immunotherapeutic Drugs Segment by Company

Johnson & Johnson

Novartis

Merck

Roche

ELI Lilly

GlaxoSmithKline

Amgen

AbbVie

AstraZeneca

Bristol-Mysers Squibb

Immunotherapeutic Drugs Segment by Type

Monoclonal Antibody

Interferon

Checkpoint Inhibitor

Vaccines

Immunotherapeutic Drugs Segment by Application

Hospitals

Clinics

Other

Immunotherapeutic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immunotherapeutic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immunotherapeutic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immunotherapeutic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Immunotherapeutic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Immunotherapeutic Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immunotherapeutic Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immunotherapeutic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Monoclonal Antibody Major Player Table 3. Interferon Major Player Table 4. Checkpoint Inhibitor Major Player Table 5. Vaccines Major Player Table 6. Global Immunotherapeutic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Major Player Table 8. Clinics Major Player Table 9. Other Major Player Table 10. Immunotherapeutic Drugs Industry Trends Table 11. Immunotherapeutic Drugs Industry Drivers Table 12. Immunotherapeutic Drugs Industry Opportunities and Challenges Table 13. Immunotherapeutic Drugs Industry Restraints Table 14. Global Immunotherapeutic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Immunotherapeutic Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Immunotherapeutic Drugs Market Share by Region (2021-2026) Table 17. Global Immunotherapeutic Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Immunotherapeutic Drugs Market Share by Region (2027-2032) Table 19. Global Immunotherapeutic Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Immunotherapeutic Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Immunotherapeutic Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Immunotherapeutic Drugs Key Players Headquarters & Area Served Table 23. Global Immunotherapeutic Drugs Players, Product Type & Application Table 24. Global Immunotherapeutic Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Immunotherapeutic Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Immunotherapeutic Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Immunotherapeutic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Immunotherapeutic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Immunotherapeutic Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Immunotherapeutic Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Immunotherapeutic Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Immunotherapeutic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Immunotherapeutic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Immunotherapeutic Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Immunotherapeutic Drugs Revenue Market Share by Application (2027-2032) Table 37. Johnson & Johnson Company Information Table 38. Johnson & Johnson Business Overview Table 39. Johnson & Johnson Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Johnson & Johnson Immunotherapeutic Drugs Product Portfolio Table 41. Johnson & Johnson Recent Development Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Novartis Immunotherapeutic Drugs Product Portfolio Table 46. Novartis Recent Development Table 47. Merck Company Information Table 48. Merck Business Overview Table 49. Merck Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Merck Immunotherapeutic Drugs Product Portfolio Table 51. Merck Recent Development Table 52. Roche Company Information Table 53. Roche Business Overview Table 54. Roche Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Roche Immunotherapeutic Drugs Product Portfolio Table 56. Roche Recent Development Table 57. ELI Lilly Company Information Table 58. ELI Lilly Business Overview Table 59. ELI Lilly Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. ELI Lilly Immunotherapeutic Drugs Product Portfolio Table 61. ELI Lilly Recent Development Table 62. GlaxoSmithKline Company Information Table 63. GlaxoSmithKline Business Overview Table 64. GlaxoSmithKline Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. GlaxoSmithKline Immunotherapeutic Drugs Product Portfolio Table 66. GlaxoSmithKline Recent Development Table 67. Amgen Company Information Table 68. Amgen Business Overview Table 69. Amgen Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Amgen Immunotherapeutic Drugs Product Portfolio Table 71. Amgen Recent Development Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. AbbVie Immunotherapeutic Drugs Product Portfolio Table 76. AbbVie Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. AstraZeneca Immunotherapeutic Drugs Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Bristol-Mysers Squibb Company Information Table 83. Bristol-Mysers Squibb Business Overview Table 84. Bristol-Mysers Squibb Immunotherapeutic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Bristol-Mysers Squibb Immunotherapeutic Drugs Product Portfolio Table 86. Bristol-Mysers Squibb Recent Development Table 87. North America Immunotherapeutic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Immunotherapeutic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Immunotherapeutic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Immunotherapeutic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Immunotherapeutic Drugs Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Immunotherapeutic Drugs Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Immunotherapeutic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Immunotherapeutic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Immunotherapeutic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Immunotherapeutic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Immunotherapeutic Drugs Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Immunotherapeutic Drugs Revenue by Country (US$ Million) & (2027-2032) Table 101. China Immunotherapeutic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 102. China Immunotherapeutic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 103. China Immunotherapeutic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 104. China Immunotherapeutic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Immunotherapeutic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Immunotherapeutic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Immunotherapeutic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Immunotherapeutic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Immunotherapeutic Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Immunotherapeutic Drugs Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Immunotherapeutic Drugs Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Immunotherapeutic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Immunotherapeutic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Immunotherapeutic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Immunotherapeutic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Immunotherapeutic Drugs Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Immunotherapeutic Drugs Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Immunotherapeutic Drugs Image Figure 2. Global Immunotherapeutic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immunotherapeutic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Monoclonal Antibody Image Figure 5. Interferon Image Figure 6. Checkpoint Inhibitor Image Figure 7. Vaccines Image Figure 8. Global Immunotherapeutic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Immunotherapeutic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Other Image Figure 13. Global Immunotherapeutic Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Immunotherapeutic Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Immunotherapeutic Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Immunotherapeutic Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Immunotherapeutic Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Immunotherapeutic Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Immunotherapeutic Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Immunotherapeutic Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Immunotherapeutic Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Immunotherapeutic Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Immunotherapeutic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Immunotherapeutic Drugs Revenue Share by Type (2021-2032) Figure 26. North America Immunotherapeutic Drugs Revenue Share by Application (2021-2032) Figure 27. North America Immunotherapeutic Drugs Revenue Share by Country (2021-2032) Figure 28. United States Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Immunotherapeutic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Immunotherapeutic Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Immunotherapeutic Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Immunotherapeutic Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Immunotherapeutic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Immunotherapeutic Drugs Revenue Share by Type (2021-2032) Figure 45. China Immunotherapeutic Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Immunotherapeutic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Immunotherapeutic Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Immunotherapeutic Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Immunotherapeutic Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Immunotherapeutic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Immunotherapeutic Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Immunotherapeutic Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Immunotherapeutic Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Immunotherapeutic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Interferon
  • Checkpoint Inhibitor
  • Vaccines
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • ELI Lilly
  • GlaxoSmithKline
  • Amgen
  • AbbVie
  • AstraZeneca
  • Bristol-Mysers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immunotherapeutic Drugs Market by Type
  3. 1.2.1 Global Immunotherapeutic Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibody
  5. 1.2.3 Interferon
  6. 1.2.4 Checkpoint Inhibitor
  7. 1.2.5 Vaccines
  8. 1.3 Immunotherapeutic Drugs Market by Application
  9. 1.3.1 Global Immunotherapeutic Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals
  11. 1.3.3 Clinics
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Immunotherapeutic Drugs Market Dynamics
  1. 2.1 Immunotherapeutic Drugs Industry Trends
  2. 2.2 Immunotherapeutic Drugs Industry Drivers
  3. 2.3 Immunotherapeutic Drugs Industry Opportunities and Challenges
  4. 2.4 Immunotherapeutic Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Immunotherapeutic Drugs Market Perspective (2021-2032)
  2. 3.2 Global Immunotherapeutic Drugs Growth Trends by Region
  3. 3.2.1 Global Immunotherapeutic Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immunotherapeutic Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Immunotherapeutic Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Immunotherapeutic Drugs Revenue by Players
  2. 4.1.1 Global Immunotherapeutic Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Immunotherapeutic Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Immunotherapeutic Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immunotherapeutic Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Immunotherapeutic Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Immunotherapeutic Drugs Players, Product Type & Application
  8. 4.5 Global Immunotherapeutic Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Immunotherapeutic Drugs Market CR5 and HHI
  11. 4.6.3 2025 Immunotherapeutic Drugs Tier 1, Tier 2, and Tier 3
5 Immunotherapeutic Drugs Market Size by Type
  1. 5.1 Global Immunotherapeutic Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Immunotherapeutic Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Immunotherapeutic Drugs Revenue Market Share by Type (2021-2032)
6 Immunotherapeutic Drugs Market Size by Application
  1. 6.1 Global Immunotherapeutic Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Immunotherapeutic Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Immunotherapeutic Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Immunotherapeutic Drugs Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Immunotherapeutic Drugs Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Immunotherapeutic Drugs Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roche Immunotherapeutic Drugs Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 ELI Lilly
  26. 7.5.1 ELI Lilly Company Information
  27. 7.5.2 ELI Lilly Business Overview
  28. 7.5.3 ELI Lilly Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 ELI Lilly Immunotherapeutic Drugs Product Portfolio
  30. 7.5.5 ELI Lilly Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Immunotherapeutic Drugs Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Amgen
  38. 7.7.1 Amgen Company Information
  39. 7.7.2 Amgen Business Overview
  40. 7.7.3 Amgen Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Amgen Immunotherapeutic Drugs Product Portfolio
  42. 7.7.5 Amgen Recent Developments
  43. 7.8 AbbVie
  44. 7.8.1 AbbVie Company Information
  45. 7.8.2 AbbVie Business Overview
  46. 7.8.3 AbbVie Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AbbVie Immunotherapeutic Drugs Product Portfolio
  48. 7.8.5 AbbVie Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Immunotherapeutic Drugs Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 Bristol-Mysers Squibb
  56. 7.10.1 Bristol-Mysers Squibb Company Information
  57. 7.10.2 Bristol-Mysers Squibb Business Overview
  58. 7.10.3 Bristol-Mysers Squibb Immunotherapeutic Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Mysers Squibb Immunotherapeutic Drugs Product Portfolio
  60. 7.10.5 Bristol-Mysers Squibb Recent Developments
8 North America
  1. 8.1 North America Immunotherapeutic Drugs Revenue (2021-2032)
  2. 8.2 North America Immunotherapeutic Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Immunotherapeutic Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Immunotherapeutic Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Immunotherapeutic Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Immunotherapeutic Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Immunotherapeutic Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Immunotherapeutic Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Immunotherapeutic Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Immunotherapeutic Drugs Revenue by Country
  11. 8.6.1 North America Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Immunotherapeutic Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Immunotherapeutic Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Immunotherapeutic Drugs Revenue (2021-2032)
  2. 9.2 Europe Immunotherapeutic Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Immunotherapeutic Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Immunotherapeutic Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Immunotherapeutic Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Immunotherapeutic Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Immunotherapeutic Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Immunotherapeutic Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Immunotherapeutic Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Immunotherapeutic Drugs Revenue by Country
  11. 9.6.1 Europe Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Immunotherapeutic Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Immunotherapeutic Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Immunotherapeutic Drugs Revenue (2021-2032)
  2. 10.2 China Immunotherapeutic Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Immunotherapeutic Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Immunotherapeutic Drugs Revenue by Type (2027-2032)
  5. 10.3 China Immunotherapeutic Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Immunotherapeutic Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Immunotherapeutic Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Immunotherapeutic Drugs Revenue by Application (2027-2032)
  9. 10.5 China Immunotherapeutic Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immunotherapeutic Drugs Revenue (2021-2032)
  2. 11.2 Asia Immunotherapeutic Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Immunotherapeutic Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Immunotherapeutic Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Immunotherapeutic Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Immunotherapeutic Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Immunotherapeutic Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Immunotherapeutic Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Immunotherapeutic Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Immunotherapeutic Drugs Revenue by Country
  11. 11.6.1 Asia Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Immunotherapeutic Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Immunotherapeutic Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immunotherapeutic Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Immunotherapeutic Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Immunotherapeutic Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Immunotherapeutic Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Immunotherapeutic Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Immunotherapeutic Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Immunotherapeutic Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Immunotherapeutic Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Immunotherapeutic Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Immunotherapeutic Drugs Revenue by Country
  11. 12.6.1 SAMEA Immunotherapeutic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Immunotherapeutic Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Immunotherapeutic Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst